Nordic Nanovector will present at AACR
Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology, announces that a late-breaking abstract on its Phase 1/2 clinical study with Betalutin® has been accepted for presentation at the American Association For Cancer Research (AACR) annual meeting (16-20 April 2016, New Orleans, LA, USA).
The poster will provide an update of safety, clinical results and duration of response (DOR) from its ongoing Phase 1/2 study in subjects with relapsed non-Hodgkin lymphoma (NHL).
The abstract is expected to be available on the AACR website on Friday, 15 April 2016.
About the AACR annual meeting
The AACR Annual Meeting is a must-attend event for cancer researchers and the broader cancer community. This year’s theme, “Delivering Cures Through Cancer Science,” reinforces the inextricable link between research and advances in patient care. There will be a number of presentations that include exciting new data from cutting-edge clinical trials as well as companion presentations that spotlight the science behind the trials and implications for delivering improved care to patients.
This multidisciplinary program will include an outstanding roster of speakers, hundreds of invited talks, and more than 6,000 proffered papers from researchers around the globe. As always, the diversity of the AACR Annual Meeting program will give presenters a forum to share critical updates in all areas, as well as members of the audience an opportunity to actively participate in discussions with colleagues.
About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications.
Further information about the Company can be found here.